Table 2 Comparison of IPSS between group 1 and 2

From: Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

  IPSS IPSS difference a P-value
  V1 V2 V3   V1 vs V2 b V1 vs V3 b Group 1 vs 2 c
Group 1 (n=35) 16.06±6.69 11.03±5.18 8.91±4.51 7.14±4.94 <0.001 <0.001 0.401
Group 2 (n=38) 15.18±8.75 11.53±6.33 9.11±5.21 6.08±5.75 <0.001 <0.001  
  1. Group 1: those with difference of IIEF-5d8 between V3 and V1, group 2: those with difference of IIEF-5>8 between V3 and V1.
  2. Abbreviations: IIEF, international index of erectile function; IPSS, international prostate symptom score; Qmax, peak urine flow rate.
  3. aDifference of IPSS between V1 and V3.
  4. bStudent's paired t-test.
  5. cStudent's independent t-test.
  6. dFive-item version of the IIEF.